Biogen is turning to Royalty Pharma for some cash in exchange for rights to a lupus program, the companies announced ...
CMO Dietmar Berger leads Gilead's R&D efforts with 54 clinical programs, anticipating Sunlenca's HIV PrEP launch & touting no ...
Chinese API manufacturers Wuhu Nuowei Chemistry and Chengdu Innovation Pharmaceutical have been placed on US import alert ...
SpringWorks Therapeutics, a biotech potentially on the verge of being acquired, won its second FDA approval. Get ...
Health acquires Caraway Health, merging pediatric urgent care with Gen Z virtual care. The deal is another tying together two ...
Biohaven lands priority review on second-chance application for neurodegenerative drug
FDA grants priority review for Biohaven's troriluzole for spinocerebellar ataxia after real-world data submission. Decision ...
Travere Therapeutics said Tuesday it plans to ask the FDA for approval of its kidney drug Filspari in a rare condition known ...
A federal court in Massachusetts temporarily blocked the Trump administration’s new cap on indirect cost reimbursements for ...
Inventiva is trimming its pipeline and enacting layoffs in an effort to get its lead MASH drug approved, the company ...
Major pharma firms like Eli Lilly, GSK, Merck, Regeneron and Sanofi announce $35B+ in share buybacks since December, ...
Novartis acquires Anthos' abelacimab for $925M upfront and up to $3.1B total, marking CEO Bill Meury's second major exit and ...
Several brand-name drugmakers believe they will withstand any drug pricing impacts from President Donald Trump’s tariffs — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results